Similarly, CTIM-76 is undergoing phase I/II investigation in patients with platinum-resistant ovarian cancer and other CLDN6-positive advanced solid tumors, including endometrial cancer (NCT06515613). This evidence concerns the gene CLDN6 and ovarian cancer.